Virgil Schijns
Chief Scientific Officer
Immunology
ERC
Belgium
Biography
Also, Registered Qualified Person (QO) for the GMP product Gliovac/ ERC 1671 and Registered Responsible Person (RP) of the Tumor Tissue bank (TTB-The Netherlands) Guest Professor at Strathclyde University, Glasgow, Scotland, United Kingdom Professor of Immune intervention at Wageningen University, The Netherlands, Department Cell Biology & Immunology Special Professor in Immunology and Virology at North Carolina State University (NCSU), Previously, from 2008 to 2011, Virgil was Chief Technology Officer, Vice-president R&D at a Utrecht-University spin-off company, The Netherlands, a company that developed vaccines based on misfolded proteins From 2005 to 2007, principal Immunologist of Nobilon, a newly business unit of AKZONOBEL, dedicated to human vaccines Previously, more than 10 years Head of the Department of Vaccine Technology and Immunology at Intervet-AKZONOBEL Virgil has a Ph.D. from the Institute of Virology
Research Interest
Immunology
